Enzyme activated nitric oxide donors
Sugar-modified SIN-1 compositions are provided. The compositions are useful for generating NO in response to hydrolytic activity of a glycosidase specific for the O-glycosidic bond between the sugar and SIN-1 moieties. Pharmaceutical compositions containing the sugar-modified SIN-1 compositions and methods of using the compositions are also provided.
1. A linsidomine (SIN-1) comprising a sugar moiety, a SIN-1 moiety and a glycosidic bond disposed between the sugar and SIN-1 moieties, said SIN-1 having the general structure
wherein L is a bond or a bifunctional linker group and wherein R is the sugar moiety and comprises a carbohydrate.
2. The linsidomine compound SIN-1 according to claim 1 , wherein L is a bifunctional linker group.
3. The linsidomine compound SIN-1 according to claim 2 , wherein the linker group includes a carbonyl group.
4. The linsidomine compound SIN-1 according to claim 1 , wherein R is a monosaccharide.
5. The linsidomine compound SIN-1 according to claim 4 , wherein R is selected from the group consisting of glyceraldehyde, erythrose, threose, ribose, arabinose, xylose, lyxose, allose, altrose, glucose, mannose, gulose, idose, galactose, talose, erythrulose, ribulose, xylulose, psicose, fructose, sorbose, and tagatose.
6. The linsidomine compound SIN-1 according to claim 4 , wherein R is glucose.
7. The linsidomine compound SIN-1 according to claim 4 , wherein R is galactose.
8. The linsidomine compound SIN-1 according to claim 4 , wherein A is a furanose or pyranose ring structure.
9. The linsidomine compound SIN-1 according to claim 1 , wherein R is a disaccharide.
10. The linsidomine compound SIN-1 according to claim 9 , wherein R is a member selected from the group consisting of sucrose, lactose, and maltose.
11. The linsidomine compound SIN-1 according to claim 1 , wherein L Is a glycosidic bond.
12. The linsidomine compound SIN-1 according to claim 11 , wherein the glycosidic bond is in an α configuration.
13. The linsidomine compound SIN-1 according to claim 11 , wherein the glycosidic bond is in a β configuration.
14. A compound which is N-(β-D-glucopyranosyl)-carbonyl-3-morpholinosydnonimine, N-(α-glucopyranosyl)-carbonyl-3-morpholinosydnonimine, N-(β-D-galactopyranosyl)-carbonyl-3-morpholinosydnonimine, or N-(α-D-galactopyranosyl)-carbonyl-3-morpholinosydnonimine.
15. A pharmaceutical composition, comprising:
a therapeutically effective amount of a linsidomine compound SIN-1, the linsidomine compound (SIN-1) comprising a sugar moiety, a SIN-1 moiety and a glycosidic bond between the sugar and SIN-1 moieties, the linsidomine compound SIN-1 having the general structure
wherein L Is a bond or a bifunctional linker group and wherein R is the sugar moiety and comprises a carbohydrate; and
a pharmaceutically acceptable carrier.
16. A pharmaceutical composition in accordance with claim 15 , further comprising a therapeutically effective amount of a second linsidomine compound SIN-1, the second linsidomine compound (SIN-1) comprising a sugar moiety, a SIN-1 moiety and a glycosidic bond between the sugar and SIN-1 moieties, the second linsidomine compound SIN-1 having the general structure
wherein L is a bond or a bifunctional linker group and wherein R is the sugar moiety and comprises a carbohydrate.
17. A pharmaceutical composition according to claim 15 , wherein the carrier comprises a liquid vehicle.
18. A pharmaceutical composition according to claim 17 , wherein the liquid vehicle comprises a member selected from the group consisting of water, Ringers-Lactate. DMSO, ethanol, and glycerol.
19. A pharmaceutical composition according to claim 15 , wherein the carrier comprises one or more pharmaceutically acceptable excipients.
20. A pharmaceutical composition according to claim 19 , wherein said composition is in the form of a pill, tablet, lacquered tablet, coated tablet, hard gelatin capsule, soft gelatin capsule, solution, syrup, emulsion, suspension, aerosol, suppository, ointment, gel, or a paste.